Amyloid-β vaccination for Alzheimer's dementia

The Lancet

Volumn 372, Issue 9647, 2008, Pages 1381-

  McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; COMPLEMENT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; IMMUNIZATION; LETTER; NERVE CELL DEGENERATION; NEURITE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 53749096936     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61579-2     Document Type: Letter

References (4)

1. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
2. St George-Hyslop P.H., and Morris J.C. Will anti-amyloid therapies work for Alzheimer's disease?. Lancet 372 (2008) 180-181
3. McGeer P.L., and McGeer E.G. Is there a future for vaccination as a treatment for Alzheimer's disease?. Neurobiol Aging 24 (2003) 391-395
4. Schwab C., Hosokawa M., and McGeer P.L. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 182 (2004) 52-64